Skip to main content
. 2019 Dec 18;12(1):13. doi: 10.3390/cancers12010013

Figure 3.

Figure 3

PSAT1 expression status was incorporated with IDH1 mutation status and chromosome 1p19q codeletion status to provide a better prognosis prediction in LGGs in the TCGA dataset. (A) The expression status of PSAT1 was incorporated with IDH1 mutation status to separate LGG patients into four subgroups for survival analysis. (B) The expression status of PSAT1 was incorporated with chromosome 1p19q codeletion status to separate LGG patients into four subgroups for survival analysis. (C) LGG patients were divided into three subgroups according to IDH1 mutation status and chromosome 1p19q codeletion status for survival analysis. (D) The expression status of PSAT1 was incorporated with IDH1 mutation status and chromosome 1p19q codeletion status to stratify LGG patients into six subgroups for survival analysis. (E) A suggested algorithm for classifying LGG patients with the combined use of IDH1 mutation status, the expression status of PSAT1 and chromosome 1p19q codeletion status.